Anti-DPM3 antibody produced in rabbit

DPM3 (dolichyl-phosphate mannosyltransferase polypeptide 3) is a component of dolichol-P-mannose (Dol-P-Man or DPM) synthase complex, which also includes DPM1 and DPM2. It is a transmembrane protein, which resides in the endoplasmic reticulum (ER). It has two alternatively spliced isoforms, which differ in the length of their N-termini. Its transmembrane region is present in the N-terminal, and the C-terminal is hydrophilic in nature, and binds to DPM1. It is composed of 92 amino acids, and has a coiled-coil domain in its C-terminal.

Dolichol-phosphate mannosyltransferase subunit 3 recombinant protein epitope signature tag (PrEST)

All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the industry.

The Human Protein Atlas project can be subdivided into three efforts: Human Tissue Atlas, Cancer Atlas, and Human Cell Atlas. The antibodies that have been generated in support of the Tissue and Cancer Atlas projects have been tested by immunohistochemistry against hundreds of normal and disease tissues and through the recent efforts of the Human Cell Atlas project, many have been characterized by immunofluorescence to map the human proteome not only at the tissue level but now at the subcellular level. These images and the collection of this vast data set can be viewed on the Human Protein Atlas (HPA) site by clicking on the Image Gallery link. We also provide Prestige Antibodies^® protocols and other useful information.

DPM3 (dolichyl-phosphate mannosyltransferase polypeptide 3) anchors the cytosolic catalytic subunit DPM1 to the endoplasmic reticulum (ER) membrane, in the DPM complex. This complex catalyzes the conversion of GDP-mannose and dolichol-phosphate to dolichol-P-mannose. Mutation in this gene, in one female patient, was found to be linked to congenital disorders of glycosylation (CDG) type I, characterized by mild muscular dystrophy, dilated cardiomyopathy and increased levels of transaminases. Its expression is regulated by PLC (phospholipase C)γ, and it responds to androgen in non-invasive prostate cancer cells. It suppresses prostate cancer invasiveness, and promotes cell apoptosis. It might also be involved in maintaining normal cell-extracellular matrix (ECM) interactions, by regulating the normal expression of GPI-linked cell surface proteins. Mutations in this gene result in α-dystroglycanopathy, and thus, this protein acts as a link between α-dystroglycanopathy and CDG.

Prestige Antibodies^® are highly characterized and extensively validated antibodies with the added benefit of all available characterization data for each target being accessible via the Human Protein Atlas portal linked just below the product name at the top of this page. The uniqueness and low cross-reactivity of the Prestige Antibodies^® to other proteins are due to a thorough selection of antigen regions, affinity purification, and stringent selection. Prestige antigen controls are available for every corresponding Prestige Antibody and can be found in the linkage section.

Every Prestige Antibody is tested in the following ways:

• IHC tissue array of 44 normal human tissues and 20 of the most common cancer type tissues.
• Protein array of 364 human recombinant protein fragments.

Solution in phosphate-buffered saline, pH 7.2, containing 40% glycerol and 0.02% sodium azide

Corresponding Antigen APREST72976

Prestige Antibodies is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.